Edesa Biotech

Q3 FY2026 EarningsQ3 FY26 results missed consensus estimates, with a net loss of $5.4M vs. $3.9M expected, and GAAP EPS of -$0.60 vs. -$0.43 mean estimate. Operating loss widened to $5.5M (vs. -$4.0M expected) as R&D expenses surged to $4.0M due to Phase 2 vitiligo trial preparations. While zero revenue was in-line for this clinical-stage biotech, higher-than-expected professional fees and non-cash compensation drove a negative variance in bottom-line performance.